The study demonstrated that this combination significantly improved PFS (palbociclib vs placebo group: 31.8 vs 22.0 months) and ORR (palbociclib vs placebo group: 68.3% vs 42.2%), further supporting its effectiveness in HR + /HER2- advanced breast cancer patients [29]. The gene discussed is HR; the disease is breast cancer.